BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The Best Computer games Ever - 2South African army arrive in crime hotspots to help tackle gangs
- 3Israel approves death penalty law for Palestinians convicted of attacks
- 4Quantum Computing’s Next Major Breakthroughs Could Come From Australia
- 5Earth's newfound 'episodic-squishy lid' may guide our search for habitable worlds
- Katz alleges Army Radio workers misled High Court in bid to halt closure
- Picking the Right Pot for Your Plants: An Aide for Plant Devotees
- Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight
- Favored Vehicle for Seniors: Make Your Determination
- Geminid meteor shower 2025 peaks next week. Here's what you need to know about this year's best meteor shower
- Activists Took BMW and Mercedes to Court Over Gas Cars. It Didn’t Stick
- Grasping the Course of Evacuation and Extradition in U.S. Migration
- Thousands of Walgreens nasal spray bottles recalled. See which ones.
- Phenomenal Web-based MBA Stages for Proficient Headway
